After the Readout: How the Field Is Interpreting Compassā Phase 3 Psilocybin Data Post published:February 20, 2026 Post category:Analysis/News/Pα+
Q1 2026 Psychedelic Drug Development Pipeline: Bullseye Charts Post published:February 19, 2026 Post category:Analysis
Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast Post published:February 17, 2026 Post category:Analysis/News/Pα+
BREAKING: Second Positive Phase 3 for Compassā Psilocybin, Though Modest Magnitude Raises Questions Post published:February 17, 2026 Post category:Analysis/News/Pα+
Q4ā25 Psychedelic Lobbying Update Post published:February 13, 2026 Post category:Analysis/News/Pα+
Center for MINDS: Bruce Damer on Why We Need Psychedelic-Catalysed Innovation Post published:February 5, 2026 Post category:Analysis/Interviews/News
Q3 2025: Oregon Psilocybin Services Update Post published:February 2, 2026 Post category:Analysis/News/Pα+
Psychedelic Funding, Public Markets, and M&A in 2025 Post published:January 20, 2026 Post category:2025 Year in Review/Analysis/Pα+
Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions Post published:January 15, 2026 Post category:2025 Year in Review/Analysis/News/Pα+